Poziotinib

SUSPENDED · PHASE3 · NSCLC

The study has not enrolled any patients. The study design is under discussion and will likely be redesigned in consultation with the FDA.

Scientific benefit, asset-specific safety, ownership and licensing: Unknown without reviewed evidence.

Detailed evidence is available in the local Pro plan simulation.